Minerva Surgical, Inc. (UTRS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 4.60: the stock has moved about 360% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMinerva Surgical, Inc. (UTRS) trades at $0.0001. Minerva Surgical, Inc. focuses on developing and commercializing minimally invasive solutions for women's uterine healthcare needs in the United States. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for UTRS: UTRS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Minerva Surgical, Inc. (UTRS) Healthcare & Pipeline Overview
Minerva Surgical, Inc. provides minimally invasive solutions for uterine healthcare, including endometrial ablation and tissue removal systems. Targeting the U.S. market, the company serves hospitals, ambulatory surgical centers, and physician offices. It competes with other medical device companies in the women's health sector.
What Is the Investment Thesis for UTRS?
Minerva Surgical operates in the women's health medical device market, which presents both opportunities and challenges. The company's focus on minimally invasive solutions aligns with current trends in healthcare, potentially driving adoption of its products. However, the company's negative profit margin of -67.8% indicates significant challenges in achieving profitability. With a market cap of $0.00B and a high beta of 4.60, Minerva Surgical exhibits high volatility. Potential investors should carefully consider the company's financial performance and competitive landscape. Growth catalysts may include expanding market share and new product development, while risks include competition and regulatory hurdles.
Based on FMP financials and quantitative analysis
UTRS Key Highlights
Minerva Surgical operates with 174 employees, indicating a relatively small scale of operations.
- The company's gross margin stands at 54.2%, suggesting a reasonable level of efficiency in production and sales.
- The company's market capitalization is $0.00B, indicating a very small company size.
- The company's profit margin is -67.8%, indicating significant losses.
- The stock exhibits a high beta of 4.60, suggesting high volatility relative to the market.
Who Are UTRS's Competitors?
UTRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.84 | -1.12% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.10 | +0.75% | $5.63M | 30 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.75 | +0.91% | $31.7M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | +4.33% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.98 | +1.02% | $49.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.73 | +1.91% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.75 | +2.74% | $82.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.55 | +2.00% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are UTRS's Key Strengths?
Specialized focus on uterine healthcare.
- Portfolio of minimally invasive solutions.
- Established presence in the U.S. market.
- Proprietary technology in endometrial ablation.
What Are UTRS's Weaknesses?
Negative profit margin.
- Limited market capitalization.
- High beta indicating high volatility.
- Dependence on a niche market.
What Are the Key Risks for UTRS?
Financial-distress signal — its Altman Z-Score of -6.27 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies.
- Regulatory hurdles and compliance requirements.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
- Negative profit margin and financial instability.
What Are UTRS's Competitive Advantages?
- Proprietary technology in endometrial ablation and tissue removal.
- Established relationships with obstetrician-gynecologists.
- Focus on minimally invasive solutions.
What Does UTRS Do?
Minerva Surgical, Inc., established in 2008 and headquartered in Santa Clara, California, is a commercial-stage medical technology company dedicated to addressing women's uterine healthcare needs through minimally invasive solutions. The company develops, manufactures, and commercializes a range of devices designed for use by obstetrician-gynecologists in various medical settings. Minerva Surgical's product portfolio includes the Minerva ES Endometrial Ablation System and the Genesys HTA Endometrial Ablation System, both designed for endometrial ablation procedures. Additionally, the company offers the Symphion Tissue Removal System, a minimally invasive system combining bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring. The Resectr Tissue Resection Device, a handheld surgical instrument, is also part of their offerings, enabling the hysteroscopic removal and diagnosis of endometrial polyps. These products are utilized in hospitals, ambulatory surgical centers, and physician offices across the United States, reflecting the company's focus on providing versatile solutions for uterine healthcare.
What Products and Services Does UTRS Offer?
- Develops minimally invasive solutions for uterine healthcare.
- Manufactures endometrial ablation systems.
- Commercializes tissue removal systems.
- Offers the Minerva ES Endometrial Ablation System.
- Provides the Genesys HTA Endometrial Ablation System.
- Offers the Symphion Tissue Removal System.
- Provides the Resectr Tissue Resection Device.
How Does UTRS Make Money?
- Develops and manufactures medical devices for uterine healthcare.
- Sells products to hospitals, ambulatory surgical centers, and physician offices.
- Generates revenue through direct sales of its devices.
What Industry Does UTRS Operate In?
Minerva Surgical operates within the medical device industry, specifically focusing on women's health. This sector is characterized by ongoing innovation and technological advancements aimed at improving patient outcomes and reducing invasiveness of procedures. The competitive landscape includes established players and emerging companies offering similar or alternative solutions for uterine healthcare. Market trends indicate a growing demand for minimally invasive procedures, driven by patient preferences and healthcare provider adoption. Minerva Surgical's success depends on its ability to differentiate its products, navigate regulatory pathways, and effectively compete in this dynamic environment.
Who Are UTRS's Key Customers?
- Ambulatory surgical centers
- Physician offices
- Obstetrician-gynecologists
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an unknown, not an operating company
Insider Activity
12 transactions · 1 purchases, 0 sales, 11 other transactions · 12 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Earnings Track Record
Minerva Surgical, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 245.5% below estimates on average.
Financial Health
Minerva Surgical, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.27 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -49.5%, showing how much profit it generates from its asset base. A current ratio of 2.53 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Minerva Surgical, Inc. operates in the Healthcare sector. It is headquartered in Santa Clara, US. The company is led by CEO Darin Hammers. UTRS has traded publicly since 2021.
UTRS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized focus on uterine healthcare.
- Portfolio of minimally invasive solutions.
- Established presence in the U.S. market.
- Proprietary technology in endometrial ablation.
Bear Case
- Negative profit margin.
- Limited market capitalization.
- High beta indicating high volatility.
- Dependence on a niche market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
UTRS Latest News
No recent news available for UTRS.
UTRS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for UTRS.
Price Targets
Wall Street price target analysis for UTRS.
UTRS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for UTRS; grades run from A+ (80-100) to F (below 30).
Leadership: Darin Hammers
CEO
Darin Hammers serves as the CEO of Minerva Surgical, Inc. His background includes extensive experience in the medical device industry, with a focus on commercializing innovative technologies. Prior to joining Minerva Surgical, he held leadership positions at various medical device companies, overseeing sales, marketing, and product development. His expertise lies in driving market adoption of new medical devices and building strong relationships with healthcare providers. He is responsible for managing 174 employees.
Track Record: Under Darin Hammers' leadership, Minerva Surgical has focused on expanding its product portfolio and increasing market penetration in the U.S. The company has navigated regulatory challenges and continued to commercialize its minimally invasive solutions for uterine healthcare. Key milestones include securing regulatory approvals for new products and expanding the company's sales network.
UTRS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Minerva Surgical may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Wide bid-ask spreads
- Higher potential for price manipulation
- Increased risk of fraud or mismanagement
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review any available news articles or press releases about the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Check for any regulatory actions or legal proceedings involving the company.
- Company has a registered business address and contact information.
- Management team has relevant experience in the medical device industry.
- Company has patents or other intellectual property related to its products.
- Company has a website with detailed information about its products and services.
- Company's products are used by healthcare providers in the United States.
UTRS Healthcare Stock FAQ
What do analysts say about UTRS stock?
Generally, micro-cap stocks like Minerva Surgical are subject to greater price volatility and investment risk. Investors should conduct thorough due diligence and consider their own risk tolerance before investing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or delayed.